Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy.

Published

Journal Article

Individuals ineligible for interferon-based hepatitis C therapy may have a worse prognosis than patients who have failed or not received treatment.To provide information about the limitations of medical treatment of hepatitis C in real-world patients.We studied 969 treatment-ineligible patients and 403 treated patients enrolled between 1/1/01 and 6/30/06; data were collected until 3/31/13. Treatment barriers were grouped into five categories and classified as health-related or health-unrelated. Fibrosis stage was assessed initially and at the end of follow-up. Mortality was determined by search of the Social Security database. Death certificates of treatment-ineligible patients were reviewed.Initially, 288 individuals had advanced fibrosis and compensated disease; 87 untreated patients developed advanced fibrosis during follow-up. Health-related treatment barriers were more commonly associated with fibrosis progression and worse survival. During follow-up, 247 untreated patients died: 47% of liver-related and 53% of liver-unrelated causes. Patients with significant comorbid illness had the worst five- (70%) and ten-year (50.5%) survival. Despite high mortality (47%) in persons with decompensated liver disease, no treatment barrier was associated with a greater incidence of liver-related death. Only significant comorbid medical illness was an independent predictor of disease progression; however, it was not associated with a greater incidence of liver-related death. Furthermore, treated patients had better 10-year survival than untreated patients on Kaplan-Meier analysis (80.3% vs. 74.5%, P = 0.005).Many patients with hepatitis C will die of non-liver-related causes and may not be helped by anti-viral treatment.

Full Text

Cited Authors

  • Izzy, M; Jibara, G; Aljanabi, A; Alani, M; Giannattasio, E; Zaidi, H; Said, Z; Gaglio, P; Wolkoff, A; Reinus, JF

Published Date

  • June 2016

Published In

Volume / Issue

  • 6 / 2

Start / End Page

  • 100 - 108

PubMed ID

  • 27493457

Pubmed Central ID

  • 27493457

Electronic International Standard Serial Number (EISSN)

  • 2213-3453

International Standard Serial Number (ISSN)

  • 0973-6883

Digital Object Identifier (DOI)

  • 10.1016/j.jceh.2016.02.006

Language

  • eng